oceaura glp-1 patch Parche For El Cuidado Corporal Glp-1, Ligero Y oceaura glp-1 patches directions GLP-1

Results of the Phase 2 Trial on Retatrutide for Obesity Retatrutide's Phase 2 clinical trial results were published in The New England Journal of Medicine

NAFLD and NASH currently have no approved treatments though they impact 25% and 5% of U.S

Overall, the benefits of GLP-1 agonists in terms of weight loss and improved metabolic health generally outweigh the potential risks, particularly when used under the guidance of a healthcare professional

With this move, Novo Nordisk strengthens its GLP-1 portfolio in India, where it already markets Rybelsus (oral semaglutide) and Wegovy (obesity management)and enters a competitive space as Eli Lillys Mounjaro is also making inroads